We are thrilled to announce that as of July 1st, 2024, our innovative product, Vitynex, has officially been listed with the FDA. This significant milestone marks a major leap forward in our commitment to providing high-quality, effective treatments to our patients and customers.
Product Details:
- Listing Date: July 1st, 2024
- NDC: 84337-001-00
Vitynex is designed with your health in mind, offering a new option for those seeking reliable and safe treatment solutions. For more detailed information about Vitynex, including its benefits and how it can be integrated into your healthcare regimen, please visit our product page.
We look forward to your continued support and trust in us as we strive to innovate and improve our product offerings. Thank you for being part of our journey at Curapep.
For further inquiries, please contact our customer service or visit our website for more details.
Vitynex is eligible for FSAs and HSAs Reimbursement.
1 Comment. Leave new
laRV TUsviX HPn